Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Avita Medical.
As investors and industry alike try to read the tea leaves of what the upcoming change in administrations holds for the U.S., speculation abounds about what Trump 2.0 will mean for the biopharma and med-tech spaces.
The Asia Pacific med-tech market is projected to reach $140 billion in 2025 in value, growing roughly 5% per year, driven largely by a rising demand for advanced and personalized medical technologies, including telemedicine and precision medicine.
The U.K. government will unveil its 10-year health plan to transform the national health service (NHS) in the coming months. At the center of this transformation is expected to be the adoption of artificial intelligence, digital and medical technologies. However, challenges in the NHS around its ‘core technology’, data capture and interoperability must be addressed before the government’s ambition can be realized.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Genesis Medtech.
The device industry is extraordinarily dependent on administrative activity where Medicare coverage is concerned, and this was exceptionally evident in 2024 when software and digital health coverage policies remained bogged down.
RSS
